An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements August 24, 2016 Type of Cancer Solid Tumor Site Bethesda Sponsor Ignyta, Inc. Protocol Number RXDX-101-02 To Learn More Call 201-510-0910